ArticleJournal of nanobiotechnology2022
Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy.
Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Platinum-based functional nanomaterials: mechanisms and therapeutic strategies in cancer radiotherapy sensitization.Molecular cancer · 2026Review
- Regulation of iron metabolism in ferroptosis: From mechanism research to clinical translation.Journal of pharmaceutical analysis · 2025Review
- From mitochondrial dysregulation to ferroptosis: Exploring new strategies and challenges in radioimmunotherapy (Review).International journal of oncology · 2025Review
- Review
- A Tumor Environment-Activated Photosensitized Biomimetic Nanoplatform for Precise Photodynamic Immunotherapy of Colon Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Alleviating the hypoxic tumor microenvironment with MnOJournal of nanobiotechnology · 2023Article
- Recent Metal Nanotheranostics for Cancer Diagnosis and Therapy: A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Radiotherapy-induced ferroptosis for cancer treatment.Frontiers in molecular biosciences · 2023Review
- Correction to: Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy.Journal of nanobiotechnology · 2022Article
- Ferroptosis: A potential opportunity for intervention of pre-metastatic niche.Frontiers in oncology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
backgroundAlthough concurrent chemoradiotherapy (CRT), as one of the most effective antineoplastic therapies in clinic, can successfully inhibit the growth of tumor cells, a risk of developing secondary tumor is still an insurmountable barrier in clinical practice.
resultsHerein, a new platinum prodrug composed of tannic acid (TA) and Pt
conclusionsThis work offered a new idea for combining the effective chemotherapy, RT and ferroptosis therapy to enhance the curative effect of CRT and inhibit tumor recurrence and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.